ML385: Selective NRF2 Inhibitor in Cancer and Ferroptosis Research

Executive Summary: ML385 (CAS 846557-71-9) is a small molecule inhibitor that selectively targets the NRF2 transcription factor, a key regulator of cellular defense mechanisms and therapeutic resistance in cancer models. Evidence demonstrates that ML385 blocks NRF2-dependent gene expression with an IC₅₀ of 1.9 μM in A549 non-small cell lung cancer (NSCLC) cells (APExBIO product data). In vivo, ML385 reduces tumor growth and enhances chemotherapy efficacy in NSCLC mouse models. Peer-reviewed studies confirm that ML385 can abolish neuroprotective effects mediated by NRF2 activation, notably in ferroptosis and oxidative stress contexts (Wang et al., 2024). The compound is insoluble in ethanol/water but is soluble in DMSO at ≥13.33 mg/mL, and should be stored at -20°C to maintain purity (≥98%).

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) orchestrates the transcriptional response to oxidative and electrophilic stress. Activation of NRF2 drives expression of genes involved in detoxification, antioxidant defense, and iron metabolism. In cancer, particularly NSCLC, persistent NRF2 activation contributes to multidrug resistance, tumor growth, and altered redox homeostasis. Inhibition of NRF2, therefore, allows researchers to interrogate both the adaptive and maladaptive roles of antioxidant signaling in disease models (Wang et al., 2024).

Mechanism of Action of ML385

ML385 binds to the Neh1 domain of NRF2, hindering its ability to heterodimerize with small Maf proteins and bind antioxidant response elements (ARE) in DNA. This results in dose- and time-dependent downregulation of NRF2 target genes, including HO-1 and GPX4, in cellular models. In A549 NSCLC cells, ML385 achieves NRF2 inhibition at an IC₅₀ of 1.9 μM (APExBIO). In vivo, ML385 blocks NRF2-mediated oncogenic and cytoprotective pathways, sensitizing tumors to chemotherapeutics such as carboplatin. In the context of neurodegeneration and ferroptosis, ML385 abolishes NRF2-dependent neuroprotection, establishing its utility in mechanistic studies (Wang et al., 2024).

Evidence & Benchmarks

• ML385 inhibits NRF2-dependent gene transcription in A549 NSCLC cells with an IC₅₀ of 1.9 μM (APExBIO).
• In NSCLC mouse models, ML385 reduces tumor growth and metastasis, with enhanced effects when combined with carboplatin (APExBIO).
• ML385 administration in T2DM mice abolishes artemisinin-induced neuroprotection by blocking NRF2 activation and downstream HO-1/GPX4 upregulation (Wang et al., 2024).
• ML385 is insoluble in ethanol and water, but soluble at ≥13.33 mg/mL in DMSO and should be stored at -20°C for maximum stability (APExBIO).
• Purity of supplied ML385 is typically ≥98%, and the compound is intended for research use only (APExBIO).

For a deeper exploration of ML385's selectivity and advanced workflows, see ML385: Selective NRF2 Inhibitor Empowering Cancer Research, which details troubleshooting and protocol optimization in comparison to this article, which emphasizes mechanistic and translational benchmarks.

To understand ML385’s translational impact, Disrupting Cancer Resistance and Redox Signaling: Strategic NRF2 Pathway Inhibition synthesizes recent literature, while this article anchors claims in direct peer-reviewed and product data.

Applications, Limits & Misconceptions

ML385 is widely used in cancer biology research, particularly in NSCLC models, to dissect NRF2 signaling, study mechanisms of therapeutic resistance, and investigate oxidative stress and ferroptosis. The compound is also applied in neurodegeneration studies to assess NRF2-related protective pathways. However, its use is limited to research applications, with no approval for diagnostic or clinical utility. ML385’s effects are context-dependent; for example, in the presence of strong inducers of NRF2 (such as artemisinin), ML385 reliably abolishes induced neuroprotection, as shown in T2DM mouse models (Wang et al., 2024).

Common Pitfalls or Misconceptions

• ML385 is not suitable for clinical or diagnostic applications; it is for research use only (APExBIO).
• It does not directly act as an antioxidant or iron chelator; its effects are mediated solely through NRF2 inhibition (Wang et al., 2024).
• Solubility issues arise in aqueous or ethanol-based media; DMSO is required as a solvent for stock solutions.
• Long-term storage of ML385 solutions is not recommended due to stability concerns (APExBIO).
• In models with NRF2-independent resistance, ML385 will not alter outcomes.

Workflow Integration & Parameters

Protocol Parameters

• Stock preparation: Dissolve ML385 at ≥13.33 mg/mL in DMSO to prepare a concentrated stock solution (APExBIO).
• Storage: Store solid ML385 or frozen DMSO solutions at -20°C; avoid repeated freeze-thaw cycles.
• In vitro dosing: Typical working concentrations for cell culture assays range from 1–10 μM; adjust based on cell line sensitivity and endpoint (Wang et al., 2024).
• In vivo use: For murine studies, ML385 dosing regimens are model-dependent; consult published literature for optimal dosage and scheduling (Wang et al., 2024).
• Combination therapy: Co-administer with chemotherapeutic agents (e.g., carboplatin) to assess synergistic effects in NSCLC models (APExBIO).

For advanced workflow integration, ML385: Selective NRF2 Inhibitor Advancing Cancer Research details robust in vitro/in vivo setups, complementing this article’s emphasis on protocol reproducibility and mechanistic clarity.

Conclusion & Outlook

ML385 (B8300, APExBIO) is a rigorously validated tool for selective NRF2 pathway inhibition in research, enabling direct interrogation of redox regulation, ferroptosis, and cancer resistance mechanisms. As demonstrated in both cancer and neurodegenerative models, ML385’s specificity allows for clear attribution of phenotypic changes to NRF2 activity (Wang et al., 2024). The compound’s limitations—particularly its research-only status and solubility constraints—should guide experimental design. Ongoing studies continue to refine ML385-based assays, solidifying its role in preclinical and translational research targeting the NRF2 axis.